May 4, 2018


U.S. Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549


Attn: Chris Edwards


Re: Evelo Biosciences, Inc.

Registration Statement on Form S-1

File No. 333-224278


Acceleration Request

Requested Date:

   May 8, 2018

Requested Time:

   4:00 p.m., Eastern Standard Time

Ladies and gentlemen:

In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), Morgan Stanley & Co. LLC and Cowen and Company, LLC, as representatives of the several underwriters, hereby join Evelo Biosciences, Inc. in requesting that the Securities and Exchange Commission take appropriate action to cause the Registration Statement on Form S-1 (File No. 333-224278) (the “Registration Statement”) to become effective on Tuesday, May 8, 2018, at 4:00 p.m., Eastern Standard Time, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Act, please be advised that we will take reasonable steps to secure adequate distribution of the preliminary prospectus, to underwriters, dealers, institutions and others, prior to the requested effective time of the Registration Statement.

We have been informed by the participating underwriters that they will comply with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended, to the extent applicable.

[Signature Page Follows]

Very truly yours,
By:   /s/ Jason Russell
  Name: Jason Russell
  Title: Executive Director


By:   /s/ Grant Miller
  Name: Grant Miller
  Title: Managing Director, Head of ECM


cc: Balkrishan (Simba) Gill, Ph.D., Evelo Biosciences, Inc.

Stuart Cable, Goodwin Procter LLP

Edwin O’Connor, Goodwin Procter LLP

Peter N. Handrinos, Latham & Watkins LLP

Wesley Holmes, Latham & Watkins LLP

[Signature Page to Acceleration Request]